Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5Thoracic 1Sarcoma 1Breast 1

Conditions

Lung Neoplasms 19Carcinoma, Non-Small-Cell Lung 11Small Cell Lung Carcinoma 5Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Ovarian Neoplasms 3Neoplasms, Unknown Primary 3Head and Neck Neoplasms 3Esthesioneuroblastoma, Olfactory 3Urinary Bladder Neoplasms 2Sarcoma, Kaposi 2Salivary Gland Neoplasms 2Radiation Injuries 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Drug-Related Side Effects and Adverse Reactions 2Chondrosarcoma 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2AIDS-related Kaposi sarcoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 30Nivolumab 12Carboplatin 6atezolizumab 5Trastuzumab 5aldesleukin 4Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Docetaxel 4Cyclophosphamide 4Cisplatin 4Bevacizumab 4spartalizumab 3fludarabine 3durvalumab 3Polymerase Chain Reaction 3Irinotecan 3Interleukin-2 3Gene Expression Profiling 3Blood Specimen Collection 3Biopsy 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2osimertinib 2enzalutamide 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Filgrastim × Thoracic × Clear all
NCT07064018 2025-07-14

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

University of California, Irvine

Phase 1/2 Recruiting
67 enrolled
BreastGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡